Evidence map›Paper›PMID 23507661›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2013

Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections.

Daniela M Schlatzer, Julia M Sugalski, Yanwen Chen, Jill Barnholtz-Sloan, Perica Davitkov, Fred E Hazlett, Nicholas Funderburg, Benigno Rodriguez, Michael M Lederman, Scott F Sieg and 2 more

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.International journal of molecular sciences · 2020
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Daniela M Schlatzer*Center for Proteomics and Bioinformatics; †Divisions of Infectious and Rheumatic Diseases, Department of Medicine, Case Western Reserve University, Cleveland, OH; ‡Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH; and §Veterans Administration Medical Center, Center for AIDS Research, University Hospitals of Cleveland, Cleveland, OH.
Julia M Sugalski
Yanwen Chen
Jill Barnholtz-Sloan
Perica Davitkov
Fred E Hazlett
Nicholas Funderburg
Benigno Rodriguez
Michael M Lederman
Scott F Sieg
Mark R Chance
Donald D Anthony
Case Western Reserve University · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
Proteomics of Immune Restoration and Opioid Exposure in HIV DiseaseP20DA026133 · NIDA · CASE WESTERN RESERVE UNIVERSITY · PI SIEG, SCOTT FREDERICK · 2009 to 2011
$3.0M
Role of immature DC in host defense against HCVR01DK068361 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI ANTHONY, DONALD D · 2006 to 2010
$1.3M
Role of IL28B and HIV in NK Control of HCVR21AI100809 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ANTHONY, DONALD D · 2012 to 2013
$420k
Tissue factor expression in HIV disease - Implications for cardiovascular riskK99HL108743 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI FUNDERBURG, NICHOLAS T. · 2012 to 2013
$178k
NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1TR000439NHLBI NIH HHS K99 HL108743NIAID NIH HHS AI 36219NIAID NIH HHS P30 AI036219NIAID NIH HHS R21 AI100809NIDA NIH HHS P20 DA026133NIDA NIH HHS P20-DA-026133NIDDK NIH HHS R01 DK068361NIDDK NIH HHS R01DK068361
6 · The paper itself

Abstract

backgroundHIV infection contributes to accelerated rates of progression of liver fibrosis during hepatitis C virus (HCV) infection, and HCV liver disease contributes to mortality during HIV infection. Although mechanisms underlying these interactions are not well known, soluble and cellular markers of immune activation associate with disease progression during both infections.

methodsWe identified proteins varying in expression across the plasma proteomes of subjects with untreated HIV infection, untreated HCV infection with low aspartate transaminase/platelet ratio index, untreated HCV infection with high aspartate transaminase/platelet ratio index, HIV-HCV coinfection, and controls. We examined correlations between dysregulated proteins and markers of immune activation to uncover biomarkers specific to disease states.

resultsWe observed the anticipated higher frequencies of HLA-DRCD38CD4 and CD8 T cells, higher serum soluble CD14 levels, and higher serum interleukin-6 levels for HCV- and HIV-infected groups compared with controls. Plasma proteome analysis identified 2297 peptides mapping to 227 proteins, and quantitative analysis of peptide intensity identified significant changes in 85 proteins across the 5 groups. Abundance for 7 of these proteins was validated by enzyme-linked immunosorbent assay. Forty-three of these proteins correlated with markers of immune activation, including at least 2 proteins that may directly drive T-cell activation. As a functional validation, we tested the enzymatic pathway product (lysophosphatidic acid, LPA) of one such protein, ecotonucleotide pyrophosphatase/phosphodiesterase-2, for ability to activate T cells in vitro. LPA activated T cells to express CD38 and HLA-DR.

conclusionsThese data indicate that elevated levels of ecotonucleotide pyrophosphatase/phosphodiesterase-2 and LPA during advanced HCV disease may play a role in exacerbating immune activation during HCV-HIV coinfection.

Indexed as

AdultBiomarkersCoinfectionCyclic Nucleotide Phosphodiesterases, Type 2FemaleHepatitis C, ChronicHIV InfectionsHumansLysophospholipidsMaleMiddle AgedPlasmaProteomeBiomarkersCyclic Nucleotide Phosphodiesterases, Type 2lysophosphatidic acidLysophospholipidsProteome

Identifiers

PMID23507661
PMCPMC3762939
OpenAlexW2085288050

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.